HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
Ad Campaigns United Kingdom Health

UK Marketing: EllaOne, Sudocrem And Vitabiotics Get Social

  • News

Executive Summary

Highlighting the latest social-media activity by some of the UK's biggest consumer health brands, including HRA Pharma's EllaOne, Teva's Sudocrem and Vitabiotics WellKid.

You may also be interested in...



HRA Educating Young Britons About Emergency Contraception

Over half of the UK's Generation Z have no idea how emergency contraption works. HRA Pharma is looking to change this with its Fact Not Fiction PR campaign for EllaOne.

HRA Pharma ‘Breaks The Stigma’ Of Emergency Contraception With EllaOne Podcast

By talking "candidly" about the morning after pill in a new EllaOne podcast, HRA Pharma wants to demonstrate that there is “nothing to be embarrassed about” when it comes to emergency contraception.

Europe's CBD Market In 2020: Narcotic Vs Novel Food

INFOGRAPHIC: An interactive timeline of selected HBW Insight coverage of the growing European CBD dietary supplements market in 2020. The timeline covers the main events of a rollercoaster 12 months, including the European Commission’s indecision on whether to classify CBD as narcotic or novel food and how the path forward became clear in the UK.

Table

View full table

Topics

Tags:
Ad Campaigns United Kingdom Health
UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By